Aiming to immune elimination of ovarian cancer stem cells.
Publication year
2013Source
World Journal of Stem Cells, 5, 4, (2013), pp. 149-162ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Tumorimmunology
Paediatrics - OUD tm 2017
Journal title
World Journal of Stem Cells
Volume
vol. 5
Issue
iss. 4
Page start
p. 149
Page end
p. 162
Subject
NCMLS 2: Immune Regulation; NCMLS 3: Tissue engineering and pathology; ONCOL 2: Age-related aspects of cancer; ONCOL 3: Translational research NCMLS 2: Immune RegulationAbstract
Ovarian cancer accounts for only 3% of all cancers in women, but it causes more deaths than any other gynecologic cancer. Treatment with chemotherapy and cytoreductive surgery shows a good response to the therapy. However, in a large proportion of the patients the tumor grows back within a few years. Cancer stem cells, that are less responsive to these treatments, are blamed for this recurrence of disease. Immune therapy either cellular or humoral is a novel concept to treat cancer. It is based on the notice that immune cells invade the tumor. However, the tumor invest heavily to escape from immune elimination by recruiting several immune suppressive mechanisms. These processes are normally in place to limit excessive immune activation and prevent autoimmune phenomena. Here, we discuss current knowledge about the immune (suppressive) status in ovarian cancer. Moreover, we discuss the immunological targets of ovarian cancer stem cells.
This item appears in the following Collection(s)
- Academic publications [238441]
- Electronic publications [122508]
- Faculty of Medical Sciences [90373]
- Open Access publications [97504]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.